Styrax Capital LP Purchases 18,411 Shares of Guardant Health, Inc. $GH

Styrax Capital LP grew its holdings in Guardant Health, Inc. (NASDAQ:GH) by 6.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 300,000 shares of the company’s stock after purchasing an additional 18,411 shares during the period. Guardant Health makes up about 1.9% of Styrax Capital LP’s holdings, making the stock its 16th biggest position. Styrax Capital LP’s holdings in Guardant Health were worth $27,711,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of GH. AQR Capital Management LLC increased its holdings in Guardant Health by 56.5% during the 1st quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock worth $3,012,000 after acquiring an additional 25,831 shares during the period. Empowered Funds LLC purchased a new stake in shares of Guardant Health during the 1st quarter valued at $274,000. Sei Investments Co. lifted its holdings in shares of Guardant Health by 15.8% during the 2nd quarter. Sei Investments Co. now owns 77,308 shares of the company’s stock worth $4,023,000 after acquiring an additional 10,538 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Guardant Health by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company’s stock worth $32,922,000 after acquiring an additional 54,284 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Guardant Health by 56.4% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company’s stock worth $5,800,000 after acquiring an additional 40,209 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Stock Performance

Shares of NASDAQ:GH opened at $147.33 on Monday. The stock has a fifty day simple moving average of $139.41 and a two-hundred day simple moving average of $112.02. The stock has a market capitalization of $19.54 billion, a price-to-earnings ratio of -43.46 and a beta of 1.59. Guardant Health, Inc. has a 12-month low of $40.35 and a 12-month high of $174.08.

Insider Transactions at Guardant Health

In other news, CEO Amirali Talasaz sold 210,000 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $109.89, for a total transaction of $23,076,900.00. Following the transaction, the chief executive officer directly owned 1,886,504 shares of the company’s stock, valued at $207,307,924.56. This represents a 10.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Chris Freeman sold 24,406 shares of the firm’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $118.67, for a total transaction of $2,896,260.02. Following the sale, the insider directly owned 60,034 shares in the company, valued at approximately $7,124,234.78. The trade was a 28.90% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 708,565 shares of company stock valued at $90,556,597. 5.60% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages recently weighed in on GH. Canaccord Genuity Group raised their price objective on Guardant Health from $135.00 to $205.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Morgan Stanley boosted their price objective on shares of Guardant Health from $130.00 to $175.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Piper Sandler set a $127.00 target price on Guardant Health in a report on Thursday, May 21st. Mizuho increased their price target on shares of Guardant Health from $135.00 to $175.00 and gave the stock an “outperform” rating in a research note on Monday, June 8th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Guardant Health in a research report on Thursday, July 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $160.04.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.